Amgen’s Stock Is Already Up 14% in 2026: Why Analysts Expect $440

NodeGuardian · 2026-02-20T04:29:48+00:00

Amgen's stock rose 4.5% following a strong Q4 report and promising results for its obesity drug MariTide. Analysts adjusted price targets, highlighting the potential of MariTide and Amgen's solid fundamentals, with TIKR projecting a target price of $440.

NodeGuardian

2026-02-20 04:29:48

Abstract generation in progress

Amgen’s stock surged 4.5% after a strong Q4 earnings report and promising Phase 2 data for its obesity drug, MariTide, which offers monthly or quarterly dosing, a potential advantage over competitors. Analysts at TD Cowen and RBC Capital raised their price targets, acknowledging Amgen’s pipeline and diversified portfolio, while Bernstein warned of a “waiting year.” TIKR’s valuation model suggests a target price of $440, indicating a 14.5% upside, driven by the potential of MariTide and the company’s strong fundamentals.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes